Evidence map›Paper›PMID 23344543›Full record

ReviewNature reviews. Cancer2013

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Alla Arzumanyan, Helena M G P V Reis, Mark A Feitelson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 414 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
414citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

414 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

354 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alla ArzumanyanDepartment of Biology and Sbarro Health Research Organization, College of Science and Technology, Temple University, 1900 N. 12th Street, Philadelphia, Pennsylvania 19122, USA.
Helena M G P V Reis
Mark A Feitelson

Funding

Combination therapies for chronic HBV, liver disease and cancerR01AI076535 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI FEITELSON, MARK A · 2008 to 2012
$1.8M
Beta-Catenin Signaling in HBxAg Mediated HCC.R01CA104025 · NCI · THOMAS JEFFERSON UNIVERSITY · PI FEITELSON, MARK A · 2006 to 2010
$1.3M
NCI NIH HHS CA104025NIAID NIH HHS AI076535
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal cancer, with increasing worldwide incidence, that is mainly associated with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections. There are few effective treatments partly because the cell- and molecular-based mechanisms that contribute to the pathogenesis of this tumour type are poorly understood. This Review outlines pathogenic mechanisms that seem to be common to both viruses and which suggest innovative approaches to the prevention and treatment of HCC.

Indexed as

AnimalsCarcinoma, HepatocellularHepacivirusHepatitis B, ChronicHepatitis B virusHepatitis C, ChronicHumansLiver Neoplasms

Identifiers

PMID23344543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.